



an Open Access Journal by MDPI

Ion Channels as Marine Drug Targets

Guest Editor:

Dr. Jean-Marc Sabatier

Institute of
NeuroPhysiopathology, UMR
7051, Faculté de Médecine
Secteur Nord, 51, Boulevard
Pierre Dramard—CS80011, 13344
Marseille, CEDEX 15, France

Deadline for manuscript
submissions:
closed (30 October 2020)

Message from the Guest Editor

Dear Colleagues,

Animal venoms, especially of marine origin, are rich natural sources of bioactive compounds. The molecular targets of the latter are mainly ion (i.e., sodium, potassium, calcium, and chloride) channels with their numerous variants/subtypes. These venom molecules are exhibiting diverse potencies and selectivities and may have some therapeutic potential based on their cellular targets. Over the past decade, marine molecules have been widely studied, as they represent potential drugs to treat a variety of (human) pathologies, from pain to autoimmune and neurological diseases. This Special Issue of “Marine Drugs” is devoted to the different aspects of the marine (or marine-derived) molecules, from the discovery and structural characterization to the pharmacology and molecular engineering in order to finally develop some “novel” candidate chemotherapeutic drugs targeting the ion channel(s).

Dr. Jean-Marc Sabatier
Guest Editor



mdpi.com/si/20903

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)